used IMC to compare the tumor and TME composition between pre-treatment and on-ICI treatment (anti-PD-L1 plus anti-CTLA4 combination) samples of platinum-resistant epithelial ovarian cancers and they described that on-treatment decrease in tumor cells was associated with an increased number of CD8+ T cells, the increased in CD8+ and FoxP3+ cells being more important in patients responding the best to ICI (45). The gene discussed is CD8A; the disease is neoplasm.